Welcome to our dedicated page for Oric Pharmaceuticals news (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on Oric Pharmaceuticals stock.
News and updates on ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) focus on its progress as a clinical stage oncology company developing therapies that address mechanisms of therapeutic resistance in cancer. ORIC regularly reports clinical data, operational milestones, and financial updates that are relevant to investors and observers following the ORIC stock and its development programs.
Recent news highlights include Phase 1b data for ORIC-944 (also referred to as rinzimetostat) in metastatic castration-resistant prostate cancer, where the company has discussed PSA responses, circulating tumor DNA reductions, and a safety profile described as compatible with long-term dosing when combined with androgen receptor inhibitors. ORIC also provides updates on preclinical findings for ORIC-944 in castration-sensitive prostate cancer models and KRAS G12C-mutant NSCLC and colorectal cancer models.
For enozertinib (ORIC-114), ORIC’s news flow includes late-breaking oral and poster presentations at major scientific meetings such as the ESMO Asia Congress. The company reports systemic and CNS activity in non-small cell lung cancer patients with EGFR exon 20, EGFR atypical (including PACC), and HER2 exon 20 mutations, including in patients with active brain metastases. These articles often detail objective response rates, disease control rates, intracranial responses, and safety observations from Phase 1b cohorts.
Corporate news items cover participation in healthcare conferences, strategic pipeline prioritization to focus on ORIC-944 and enozertinib, leadership appointments such as the creation of a Chief Technical Officer role, and capital raises via private placements and at-the-market programs. Financial press releases summarize quarterly results, research and development spending, and the company’s cash and investment position.
This news page aggregates ORIC’s press releases and related disclosures so readers can follow clinical trial readouts, program updates, corporate developments, and other material events affecting ORIC Pharmaceuticals and the ORIC ticker over time.
ORIC Pharmaceuticals (Nasdaq: ORIC) has announced new employee inducement grants approved on March 3, 2025. The company granted 26,450 non-qualified stock options and 4,300 restricted stock units to three new non-executive employees who joined in February 2025.
The stock options will vest 25% on the first anniversary of the Grant Date, with the remaining shares vesting monthly over three years. The restricted stock units will vest one-third annually over three years. These grants were made under the company's 2022 Inducement Equity Incentive Plan and approved by ORIC's Compensation Committee in accordance with Nasdaq Rule 5635(c)(4).
ORIC Pharmaceuticals has announced focused registrational clinical development plans for its lead programs ORIC-944 and ORIC-114, along with an extended cash runway into 2027. The company plans to initiate its first Phase 3 trial for ORIC-944 in metastatic castration resistant prostate cancer (mCRPC) in 1H 2026, while ORIC-114's registrational development will focus on first-line non-small cell lung cancer (NSCLC) with anticipated initiation in 2026.
Key milestones include combination dose escalation data for ORIC-944 expected in 1H and 2H 2025, and comprehensive NSCLC data for ORIC-114 in 2H 2025. The company reported $256 million in cash and investments as of December 31, 2024, extending their projected cash runway from late 2026 to 2027 under the refined operating plan.
ORIC Pharmaceuticals reported its Q4 and full-year 2024 financial results, highlighting significant progress in its clinical programs. The company reported cash and investments of $256 million, expected to fund operations into late 2026. Key developments include encouraging early safety and efficacy data for ORIC-944 in metastatic prostate cancer treatment and a clinical trial collaboration with Johnson & Johnson for ORIC-114.
Financial results show R&D expenses increased to $114.1 million for 2024, up from $85.2 million in 2023. G&A expenses rose to $28.8 million in 2024 from $25.6 million in 2023. The company secured a $125 million private placement financing and expects seven data readouts across its clinical programs over the next 18 months, with potential registrational trials starting in 2H25 and early 2026.
ORIC Pharmaceuticals (Nasdaq: ORIC) announced the granting of inducement equity awards to two new non-executive employees who joined the company in January 2025. The grants, approved on February 3, 2025, include 29,600 non-qualified stock options and 4,800 restricted stock units.
The stock options will vest 25% on the first anniversary of the grant date, with the remaining shares vesting monthly over the following three years. The restricted stock units will vest in three equal annual installments. These grants were made under the company's 2022 Inducement Equity Incentive Plan and approved by ORIC's Compensation Committee in accordance with Nasdaq Rule 5635(c)(4).
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical stage oncology company, has announced its participation in three major investor conferences in February 2025. The company will engage in fireside chats at the following events:
- Jones Research Precision Medicine Day on February 3 at 12:30 p.m. ET
- Guggenheim Securities SMID Cap Biotech Conference on February 5 at 1:30 p.m. ET
- Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11 at 12:00 p.m. ET
Live webcasts of these discussions will be accessible through the investor section of ORIC's website at www.oricpharma.com, with replays available for 90 days after each event.
ORIC Pharmaceuticals has reported encouraging early Phase 1b combination data for ORIC-944 in treating metastatic castration-resistant prostate cancer (mCRPC). The trial showed deep PSA decreases, with 3 of 6 patients achieving confirmed PSA50 responses and 2 achieving PSA90 responses. The treatment demonstrated favorable safety with primarily Grade 1 and 2 adverse events.
The company entered a clinical collaboration with Johnson & Johnson to evaluate ORIC-114 combined with amivantamab for first-line NSCLC treatment. ORIC expects seven data readouts across its clinical programs over the next 18 months, with potential registrational trials starting in 2H25 and early 2026.
Following a $125 million private placement financing, ORIC's cash position stood at $282.4 million as of September 30, 2024, expected to fund operations into late 2026.
ORIC Pharmaceuticals announced a clinical supply agreement with Janssen Research & Development to evaluate ORIC-114 in combination with amivantamab for the first-line treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. This Phase 1b trial is expected to begin in Q1 2025, with initial data anticipated by mid-2026.
The trial aims to assess the safety and tolerability of the combination therapy and determine the recommended Phase 2 dose (RP2D). ORIC will sponsor the trial, while Johnson & Johnson will supply amivantamab.
ORIC retains the development and commercial rights to ORIC-114 and may expand its use with other agents. The company highlighted that ORIC-114 has shown promising systemic and intracranial activity in heavily pre-treated patients with EGFR/HER2 mutated NSCLC. The trial will further explore its efficacy in the first-line setting, both as a monotherapy and in combination with amivantamab.
In 2024, ORIC completed the monotherapy dose escalation portion of the Phase 1b trial for ORIC-114 in patients with advanced solid tumors. Based on these data, two provisional RP2D levels (80 mg and 120 mg QD) were selected for further evaluation.
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical stage oncology company specializing in treatments for therapeutic resistance, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's CEO, Jacob M. Chacko, M.D., will deliver a company overview presentation on Tuesday, January 14, 2025, at 11:15 a.m. PT.
The presentation will be accessible via live webcast through the investor section of ORIC's website at www.oricpharma.com. Interested parties who cannot attend the live presentation will have access to a replay of the webcast, which will remain available for 90 days after the event.
ORIC Pharmaceuticals (Nasdaq: ORIC) has announced the granting of inducement awards to a new non-executive employee who joined in December 2024. The grants, approved on January 2, 2025, include 16,400 non-qualified stock options and 2,800 restricted stock units.
The stock options will vest 25% on the first anniversary of the grant date, with the remaining shares vesting monthly over the following three years. The restricted stock units will vest in three equal installments on each anniversary of the grant date. The exercise price for the stock options is set at the closing price of ORIC's common stock on January 2, 2025.
These inducement grants were made under the company's 2022 Inducement Equity Incentive Plan and were approved by ORIC's Compensation Committee in accordance with Nasdaq Rule 5635(c)(4).
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical stage oncology company, announced its participation in two upcoming investor conferences in December 2024. The company will join a fireside chat at the 7th Annual Evercore HEALTHCONx Conference on December 4 at 2:35 p.m. ET, and participate in the 'Novel Mechanisms in Oncology II' panel at Citi's 2024 Global Healthcare Conference on December 5 at 11:00 a.m. ET. Live webcasts will be accessible through ORIC's website, with replays available for 90 days after the events.